NICE recommends tirzepatide for obesity

In December 2024, the National Institute for Health and Care Excellence (NICE) published technology appraisal TA1026, recommending tirzepatide (Mounjaro) for managing overweight and obesity in adults on the NHS. The guidance was last updated in September 2025 to reflect implementation arrangements.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class to receive a positive NICE appraisal for obesity. It joins semaglutide (Wegovy), which received its own NICE recommendation (TA875) in 2023.

Eligibility criteria

Under TA1026, tirzepatide is recommended as an option for managing overweight and obesity in adults who meet specific criteria, including:

  • A BMI of at least 35 kg/m² (or lower thresholds for certain ethnic minority groups), or
  • A BMI of 30–34.9 kg/m² with weight-related comorbidities.

It is intended for use alongside a reduced-calorie diet and increased physical activity.

NICE recommends a 2-year treatment review point, at which clinicians should assess whether continued treatment is appropriate.

Implementation: phased rollout

NICE acknowledged that NHS capacity constraints would prevent immediate full implementation. The guidance was updated in September 2025 with details on a phased rollout, prioritising patients with the highest clinical need. This phased approach reflects the significant demand for GLP-1-class obesity treatments across the NHS.

Why this matters for peptide research

The NICE appraisal of tirzepatide is significant for the peptide research community for several reasons:

  • Clinical validation of dual agonism: The recommendation underscores the clinical efficacy of simultaneous GIP and GLP-1 receptor agonism — the mechanism behind tirzepatide's weight loss effects. This supports continued research into dual and triple agonist peptides.

  • Regulatory precedent: TA1026 establishes a UK regulatory pathway for next-generation incretin peptides. Future peptides targeting GIP, GLP-1, and glucagon receptors (such as retatrutide and survodutide) will be measured against the clinical and cost-effectiveness benchmarks set here.

  • Market context: The NHS approval increases legitimate clinical access to tirzepatide, which may affect the research-grade peptide market. Researchers should note that tirzepatide is a POM and that research-grade material is not a substitute for the regulated pharmaceutical product.

Related compounds

For further reading, see our compound profiles for tirzepatide, semaglutide, retatrutide, cagrilintide, and CagriSema.

UK regulatory status

Tirzepatide (Mounjaro) is a Prescription-Only Medicine (POM) licensed in the UK for both type 2 diabetes and weight management. Research-grade tirzepatide is not a licensed medicine and must not be represented as such. Research peptides are legal for research purposes but are not licensed for human consumption.

This article is for research and educational purposes only and does not constitute medical advice.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.